Valuation: Ipca Laboratories Limited

Market Cap 499B 5.21B 4.52B 4.26B 3.87B 7.25B 7.3B 50.89B 19.61B 253B 19.57B 19.14B 805B P/E 2027 *
32.9x
P/E 2028 * 28.2x
Enterprise Value 489B 5.1B 4.42B 4.17B 3.78B 7.1B 7.15B 49.8B 19.19B 248B 19.15B 18.73B 788B EV / Sales 2027 *
4.45x
EV / Sales 2028 * 3.91x
Free-Float
54.94%
Yield 2027 *
0.29%
Yield 2028 * 0.31%
1 day-0.03%
1 week+0.53%
Current month-0.28%
1 month+13.60%
3 months+24.20%
6 months+26.19%
Current year+38.30%
1 week 1,947.3
Extreme 1947.3
1,995
1 month 1,800.35
Extreme 1800.35
1,999
Current year 1,392
Extreme 1392
1,999
1 year 1,252.95
Extreme 1252.95
1,999
3 years 878.45
Extreme 878.45
1,999
5 years 670
Extreme 670
1,999
10 years 200
Extreme 200
1,999
Manager TitleAgeSince
Chief Executive Officer 53 01/04/2023
Chief Executive Officer 70 01/04/2023
Chief Tech/Sci/R&D Officer 52 16/10/2023
Director TitleAgeSince
Chairman 79 05/07/2012
Director/Board Member 53 11/11/2008
Director/Board Member 70 01/08/1994
Change 5-day change 1-year change 3-year change Capi.($)
-0.03%+0.53% - - 5.23B
+2.02%-0.96%+50.69%+92.40% 994B
+0.28%-3.24%+49.57%+62.65% 640B
+1.81%+2.07%+19.89%+70.38% 454B
+5.00%+2.21%+36.64%+39.24% 337B
+1.68%-9.20%+15.25%+24.87% 261B
+3.81%+0.93%+3.05%+12.39% 246B
+1.10%-12.75%+38.03%+45.44% 204B
+1.43%-6.21%-19.49%-58.94% 190B
+1.87%-3.04%+27.81%+89.26% 178B
Average +1.80%-4.63%+24.60%+41.97% 389.42B
Weighted average by Cap. +1.60%-3.19%+33.46%+57.27%

Financials

2027 *2028 *
Net sales 110B 1.15B 994M 938M 851M 1.6B 1.61B 11.2B 4.32B 55.78B 4.31B 4.21B 177B 123B 1.28B 1.11B 1.05B 949M 1.78B 1.79B 12.5B 4.82B 62.23B 4.81B 4.7B 198B
Net income 15.15B 158M 137M 129M 117M 220M 221M 1.54B 595M 7.68B 593M 580M 24.43B 17.8B 186M 161M 152M 138M 258M 260M 1.81B 699M 9.03B 697M 682M 28.7B
Net Debt -10.65B -111M -96.28M -90.86M -82.43M -155M -156M -1.09B -418M -5.4B -417M -408M -17.18B -19.96B -208M -180M -170M -154M -290M -292M -2.03B -784M -10.12B -782M -765M -32.19B
Logo Ipca Laboratories Limited
Ipca Laboratories Limited is an India-based integrated pharmaceutical company. The Company is engaged in manufacturing and marketing over 350 formulations and approximately 80 active pharmaceutical ingredients (APIs) covering various therapeutic segments. It offers APIs, such as Atenolol, Chloroquine Phosphate, Chlorthalidone, Furosemide, Hydroxychloroquine sulfate, Losartan, Metoprolol Succinate, Metoprolol Tartrate, Pyrantel Salts and Propranolol. The Company offers brands, such as Zerodol, Lariago, HCQS, Perinorm, Rapither AB, Tenoric, Lumerax, Etova, Fexova, Malirid, Allsuth, Alwiz, AZR 50mg, Bacilon, Cinkona, Clarbact, Glyree MV, Halotop, Luliz, Ozepam, Pacimol, Pari, Xtor-F, Zabpro, Zilast, Ramcor, Sove, Venpower and Folitrax. The Company’s products are sold in over 100 countries across the globe. The Company has 18 manufacturing units in India manufacturing APIs and formulations. Its subsidiaries include Ipca Pharmaceuticals, Inc. and Ipca Pharma Nigeria Ltd.
Employees
17,210
Date Price Change Volume
11/09/26 ₹1,969.50 -0.03% 20,545
10/09/26 ₹1,970.10 +0.33% 107,603
09/09/26 ₹1,963.70 -0.21% 5,626
08/09/26 ₹1,967.80 +0.44% 12,948
Trader
Investor
Global
Quality
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
1,968.50INR
Average target price
1,972.28INR
Spread / Average Target
+0.19%

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!